3 stocks whose trading volume is giving them a new direction

In the markets, we often hear about indicators, charts and trend lines to help investors make decisions. But what gets lost in this deluge of data is the very foundation - trading volume. For it is volume that reveals the market's true beliefs about the price movement of a stock or ETF, and those who understand this factor have an edge over others.

Call option volume is a particularly interesting indicator because it provides important information about expected price movements. Investors betting on call options are showing their confidence in growth. This article will focus on three stocks where trading volume signals potential growth: Cameco as a bet on nuclear power, Pfizer as an undervalued healthcare giant, and regional banks benefiting from interest rate changes.

Cameco: The future of energy

With the growing demand for technological innovations such as artificial intelligence and quantum computing, the issue of sustainable energy is becoming more pressing. Nuclear power, which can cope with demanding energy requirements, is thus coming to the fore.

As a key player in the uranium sector, Cameco $CCJ has seen a significant increase in call options trading, reaching a volume of 384,705 contracts. These numbers indicate strong investor confidence in the company's future growth. Moreover, Wall Street analysts estimate a target price of $66.6 per share, representing a potential upside of tens of percent.

Further evidence of growing confidence is the 9.3% decline in short positions over the past month, suggesting that investors are retreating from a bearish stance.

Pfizer: a healthcare giant at a bargain price

Shares of Pfizer $PFE are currently trading at a significant discount to their 2022 highs. With a price-to-book (P/B) ratio of 1.7x compared to the sector average of 4.8x, Pfizer is a clear opportunity for value investors.

Call options on Pfizer reached a volume of 201,090 contracts in December 2024, well above the average. This increase suggests an impending catalyst that could support share price growth. Analysts at Guggenheim maintain a Buy rating with a target price of $33 per share, representing a potential upside of 25%.

Similar to Cameco, there was a decrease in short positions, specifically by 5.5%, confirming investor optimism about the future.

Regional banks: Profit from interest rate cuts

The Federal Reserve (Fed) has begun a cycle of interest rate cuts, bringing new opportunities for regional banks. Lower rates are boosting consumer lending such as mortgages, credit cards and auto loans, which can increase the profitability of these banks.

An ETF focused on regional banks, the SPDR S&P Regional Banking ETF $KRE, is seeing increased call option activity, indicating investor confidence in the sector's growth. In addition, the ETF offers a dividend yield of 2.42%, adding appeal for long-term investors.

Disclaimer: There is plenty of inspiration to be found on Bulios, however, stock selection and portfolio construction is entirely up to you, so always conduct thorough self-analysis.

Source: Marketbeat